Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multidrug resistance

T Tsuruo1, A Tomida

  • 1Institute of Molecular and Cellular Biosciences, University of Tokyo, Japan.

Anti-Cancer Drugs
|April 1, 1995
PubMed
Summary
This summary is machine-generated.

Researchers identified MS-209 and PSC-833 as effective multidrug resistance (MDR) reversing agents. These compounds, along with an antibody, show promise for treating drug-resistant cancers by targeting P-glycoprotein.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glucose-regulated protein 78: a new partner of p53 in trophoblast.

Proteomics·2009
Same author

Reversal of multidrug resistance by novel nitrophenyl pyrones, SNF4435C and D.

Japanese journal of cancer research : Gann·2001
Same author

Dephosphorylated hypoxia-inducible factor 1alpha as a mediator of p53-dependent apoptosis during hypoxia.

Oncogene·2001
Same author

Neutral taxoids from Taxus cuspidata as modulators of multidrug-resistant tumor cells.

Phytochemistry·2000
Same author

Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs.

Cancer research·2000
Same author

Drug resistance mediated by cellular stress response to the microenvironment of solid tumors.

Anti-cancer drug design·1999
Same journal

Akt inhibitor-IV in estrogen receptor-positive breast cancer cells: cytotoxic, apoptotic, transcriptional, and in-silico comparison with tamoxifen.

Anti-cancer drugs·2026
Same journal

Prolonged multimodal disease control with trifluridine/tipiracil plus bevacizumab in KRAS-mutant metastatic rectal cancer: a case report.

Anti-cancer drugs·2026
Same journal

Growth differentiation factor-11 inhibits the progression of acute myeloid leukemia and increases chemosensitivity by inhibiting cathepsin S.

Anti-cancer drugs·2026
Same journal

Inavolisib and lenvatinib for PIK3CA-mutated refractory splenic angiosarcoma: a case report.

Anti-cancer drugs·2026
Same journal

Drug repurposing of liver cancer based on multimodal neural network and virtual screening.

Anti-cancer drugs·2026
Same journal

Discovery of an orally active and liver-targeted dual prodrug of 5-fluoro-2'-deoxyuridine-5'-monophosphate for the treatment of hepatocellular carcinoma.

Anti-cancer drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Oncology
  • Biochemistry

Background:

  • Multidrug resistance (MDR) is a major challenge in cancer chemotherapy.
  • Verapamil was identified as an MDR reversing agent in 1981.
  • Effective MDR reversing agents require potent effects with minimal side effects.

Purpose of the Study:

  • To identify novel compounds that can reverse multidrug resistance.
  • To evaluate the efficacy of MS-209 and PSC-833 as MDR reversing agents.
  • To assess the therapeutic potential of P-glycoprotein targeting agents.

Main Methods:

  • In vitro and in vivo studies were conducted.
  • Interaction of compounds with P-glycoprotein was investigated.
  • Therapeutic effects of an antibody against P-glycoprotein were evaluated.

Related Experiment Videos

Main Results:

  • MS-209 and PSC-833 demonstrated significant MDR reversing effects.
  • These compounds directly interacted with P-glycoprotein.
  • MRK16, an antibody against P-glycoprotein, showed therapeutic efficacy against drug-resistant human tumors.

Conclusions:

  • MS-209 and PSC-833 are promising MDR reversing agents.
  • P-glycoprotein targeting agents, including antibodies, hold potential for cancer therapy.
  • Further clinical investigation of MS-209, PSC-833, and anti-P-glycoprotein antibodies is warranted.